Publication:
Immune responses to hepatitis B vaccination after hematopoietic stem cell transplantation in pediatric and young adult patients

dc.contributor.authorKrittiya Chaichotjindaen_US
dc.contributor.authorUsanarat Anurathapanen_US
dc.contributor.authorSophida Boonsathornen_US
dc.contributor.authorSujittra Chaisavaneeyakornen_US
dc.contributor.authorSuporn Treepongkarunaen_US
dc.contributor.authorChonnamet Techasaensirien_US
dc.contributor.authorNopporn Apiwattanakulen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.date.accessioned2020-10-05T06:37:39Z
dc.date.available2020-10-05T06:37:39Z
dc.date.issued2020-01-01en_US
dc.description.abstract© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Background: Hematopoietic stem cell transplantation (HSCT) recipients require hepatitis B (HBV) revaccination. Hepatitis B surface antibody (anti-HBs) seroconversion rates after revaccination range from 64% to 79% in these patients. The seroconversion rate and factors associated with non-seroconversion have not been clearly elucidated in pediatric and young adult recipients after HSCT. Objectives: To evaluate anti-HBs seroconversion rates in pediatric and young adult patients revaccinated after HSCT, and to identify factors associated with non-seroconversion. Method: The current study was prospective and cross-sectional. Post-HSCT recipients aged ≤25 years who had completed a course of three HBV revaccinations were recruited, and their anti-HBs titers were assessed. Non-seroconverted patients were administered a fourth vaccination. Those who subsequently remained seronegative were administered two additional vaccinations. Those who remained seronegative after all six vaccinations were defined as non-responders. Results: A total of 118 patients were enrolled. The HBV-containing vaccines used included DTaP-IPV-HBV-Hib, DTwP-HBV-Hib, and monovalent vaccines. The anti-HBs seroconversion rate after three revaccinations was 82% (95% confidence interval [CI], 73.7-89.2). One patient (0.8%) was classified as non-responder. Factors associated with non-seroconversion after three revaccinations included cytomegalovirus (CMV) reactivation (odds ratio [OR] 10.63, 95% CI 1.16-97.00), anti-HBs seronegativity before HSCT (OR 7.01, 95% CI 1.55-31.78) and three DTwP-HBV-Hib revaccinations (OR 11.71, 95% CI 1.43-96.26). Conclusion: In the current study the anti-HBs seroconversion rate after three HBV revaccinations was excellent. CMV reactivation, anti-HBs seronegativity before HSCT, and three DTwP-HBV-Hib revaccinations were associated with non-seroconversion, but the non-responder rate was low.en_US
dc.identifier.citationClinical Transplantation. (2020)en_US
dc.identifier.doi10.1111/ctr.14024en_US
dc.identifier.issn13990012en_US
dc.identifier.issn09020063en_US
dc.identifier.other2-s2.0-85090143306en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/59260
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85090143306&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleImmune responses to hepatitis B vaccination after hematopoietic stem cell transplantation in pediatric and young adult patientsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85090143306&origin=inwarden_US

Files

Collections